<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01762813</url>
  </required_header>
  <id_info>
    <org_study_id>29034/2012</org_study_id>
    <nct_id>NCT01762813</nct_id>
  </id_info>
  <brief_title>Assessment of Clinically Related Outcomes and Biomarker Analysis for Translational Integration in Colorectal Cancer</brief_title>
  <acronym>ACROBATICC</acronym>
  <official_title>Prospective, Population-based Cohort Collection of Blood Samples and Tumor Tissue From Patients Operated on for Primary or Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helse Stavanger HF</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  A prospective, observational study on clinical outcomes of surgical management of
           primary and metastatic colorectal cancer

        -  Prospective collection of tissues to explore potential biomarkers in blood and/or
           primary or secondary cancers and/or normal colon
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective project in collecting and assessing clinical outcomes data related to molecular
      profiling of tumors based on cancer primary or metastatic tissue or tissue from peripheral
      blood samples. As a future part of the project will be collected patient reported outcomes
      (PROs) for assessing clinical outcomes in relation to clinical pathways, patient reported
      results, as well as tumor profiling by molecular methods.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2012</start_date>
  <completion_date type="Anticipated">December 2027</completion_date>
  <primary_completion_date type="Anticipated">December 2027</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cancer-specific survival</measure>
    <time_frame>5-years</time_frame>
    <description>Time from surgery to death of cancer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free survival</measure>
    <time_frame>3 and 5 years</time_frame>
    <description>Time from surgery to recurrence of cancer</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>open and laparoscopic surgery</arm_group_label>
    <description>Patients with primary and or metastatic colorectal cancer (CRC) eligible for curative surgery will be included. Subcohorts may be based on either colon cancer, rectal cancer, metastatic cancer, surgery (laparoscopy or open), node negative and node positive disease, and molecular profiling.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>open and laparoscopic surgery</intervention_name>
    <description>Curative surgery for either primary (colorectal cancer, crc) or metastatic CRC (liver surgery)</description>
    <arm_group_label>open and laparoscopic surgery</arm_group_label>
    <other_name>Liver surgery</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, whole blood, plasma, cancer tissue, normal tissue.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with colorectal cancer (primary and/or secondary) undergoing surgery for
        curative intent
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of colorectal cancer, primary or metastatic (liver), with a treatment
             intention of planned curative surgery

          -  Informed consent to participate

          -  Age ≥18

        Exclusion Criteria:

          -  failure to provide written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kjetil Søreide, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helse Stavanger HF</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ramesh Kajavi, RN</last_name>
    <phone>92297672</phone>
    <phone_ext>47</phone_ext>
    <email>acro.gitan@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin Watson, MSc</last_name>
    <email>martin.watson@sus.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <zip>4068</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kjetil Søreide, MD, PhD</last_name>
      <phone>92281557</phone>
      <phone_ext>47</phone_ext>
      <email>ksoreide@mac.com</email>
    </contact>
    <investigator>
      <last_name>Kjetil Søreide, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/27357108</url>
    <description>ACROBATICC protocol paper</description>
  </link>
  <reference>
    <citation>Søreide K, Watson MM, Lea D, Nordgård O, Søreide JA, Hagland HR; ACROBATICC collaborators. Assessment of clinically related outcomes and biomarker analysis for translational integration in colorectal cancer (ACROBATICC): study protocol for a population-based, consecutive cohort of surgically treated colorectal cancers and resected colorectal liver metastasis. J Transl Med. 2016 Jun 29;14(1):192. doi: 10.1186/s12967-016-0951-4.</citation>
    <PMID>27357108</PMID>
  </reference>
  <results_reference>
    <citation>Hagland HR, Lea D, Watson MM, Søreide K. Correlation of Blood T-Cells to Intratumoural Density and Location of CD3(+) and CD8(+) T-Cells in Colorectal Cancer. Anticancer Res. 2017 Feb;37(2):675-683.</citation>
    <PMID>28179316</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2013</study_first_submitted>
  <study_first_submitted_qc>January 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2013</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colon cancer</keyword>
  <keyword>rectal cancer</keyword>
  <keyword>liver metastasis</keyword>
  <keyword>survival</keyword>
  <keyword>biomarker</keyword>
  <keyword>molecular profile</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Raw data may be provided given appropriate consent and approval for anonymous database sharing</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://translational-medicine.biomedcentral.com/articles/10.1186/s12967-016-0951-4</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

